Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

Influence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in Europe

Authors: Dilip Nathwani, Christian Eckmann, Wendy Lawson, Caitlyn T Solem, Shelby Corman, Jennifer M Stephens, Cynthia Macahilig, Damien Simoneau, Richard Chambers, Jim Z Li, Seema Haider

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

Patient-related (demographic/disease) and treatment-related (drug/clinician/hospital) characteristics were evaluated as potential predictors of healthcare resource use and opportunities for early switch (ES) from intravenous (IV)-to-oral methicillin-resistant Staphylococcus aureus (MRSA)-active antibiotic therapy and early hospital discharge (ED).

Methods

This retrospective observational medical chart study analyzed patients (across 12 European countries) with microbiologically confirmed MRSA complicated skin and soft tissue infections (cSSTI), ≥3 days of IV anti-MRSA antibiotics during hospitalization (July 1, 2010-June 30, 2011), and discharged alive by July 31, 2011. Logistic/linear regression models evaluated characteristics potentially associated with actual resource use (length of IV therapy, length of hospital stay [LOS], IV-to-oral antibiotic switch), and ES and ED (using literature-based and expert-verified criteria) outcomes.

Results

1542 patients (mean ± SD age 60.8 ± 16.5 years; 61.5% males) were assessed with 81.0% hospitalized for MRSA cSSTI as the primary reason. Several patient demographic, infection, complication, treatment, and hospital characteristics were predictive of length of IV therapy, LOS, IV-to-oral antibiotic switch, or ES and ED opportunities. Outcomes and ES and ED opportunities varied across countries. Length of IV therapy and LOS (r = 0.66, p < 0.0001) and eligibilities for ES and ED (r = 0.44, p < 0.0001) showed relatively strong correlations. IV-to-oral antibiotic switch patients had significantly shorter length of IV therapy (−5.19 days, p < 0.001) and non-significantly shorter LOS (−1.86 days, p > 0.05). Certain patient and treatment characteristics were associated with increased odds of ES (healthcare-associated/ hospital-acquired infection) and ED (patient living arrangements, healthcare-associated/ hospital-acquired infection, initiating MRSA-active treatment 1–2 days post cSSTI index date, existing ED protocol), while other factors decreased the odds of ES (no documented MRSA culture, ≥4 days from admission to cSSTI index date, IV-to-oral switch, IV line infection) and ED (dementia, no documented MRSA culture, initiating MRSA-active treatment ≥3 days post cSSTI index date, existing ES protocol).

Conclusions

Practice patterns and opportunity for further ES and ED were affected by several infection, treatment, hospital, and geographical characteristics, which should be considered in identifying ES and ED opportunities and designing interventions for MRSA cSSTI to reduce IV days and LOS while maintaining the quality of care.
Appendix
Available only for authorised users
Literature
2.
go back to reference Edelsberg J, Berger A, Weber DJ, Mallick R, Kuznik A, Oster G: Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol. 2008, 29 (2): 160-169. 10.1086/526444.CrossRefPubMed Edelsberg J, Berger A, Weber DJ, Mallick R, Kuznik A, Oster G: Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol. 2008, 29 (2): 160-169. 10.1086/526444.CrossRefPubMed
3.
go back to reference Hatoum HT, Akhras KS, Lin SJ: The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn Microbiol Infect Dis. 2009, 64 (3): 305-310. 10.1016/j.diagmicrobio.2009.02.005.CrossRefPubMed Hatoum HT, Akhras KS, Lin SJ: The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn Microbiol Infect Dis. 2009, 64 (3): 305-310. 10.1016/j.diagmicrobio.2009.02.005.CrossRefPubMed
4.
go back to reference Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM: Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol. 2007, 28 (11): 1290-1298. 10.1086/520743.CrossRefPubMed Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM: Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol. 2007, 28 (11): 1290-1298. 10.1086/520743.CrossRefPubMed
5.
go back to reference Bamford KB, Desai M, Aruede MJ, Lawson W, Jacklin A, Franklin BD: Patients' views and experience of intravenous and oral antimicrobial therapy: room for change. Injury. 2011, 42 (Suppl 5): S24-S27.CrossRefPubMed Bamford KB, Desai M, Aruede MJ, Lawson W, Jacklin A, Franklin BD: Patients' views and experience of intravenous and oral antimicrobial therapy: room for change. Injury. 2011, 42 (Suppl 5): S24-S27.CrossRefPubMed
6.
go back to reference Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H: Answering patients' needs: oral alternatives to intravenous therapy. Oncologist. 2001, 6 (Suppl 4): 12-16.CrossRefPubMed Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H: Answering patients' needs: oral alternatives to intravenous therapy. Oncologist. 2001, 6 (Suppl 4): 12-16.CrossRefPubMed
8.
go back to reference Sader HS, Farrell DJ, Jones RN: Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. Int J Antimicrob Agents. 2010, 36 (1): 28-32. 10.1016/j.ijantimicag.2010.03.016.CrossRefPubMed Sader HS, Farrell DJ, Jones RN: Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. Int J Antimicrob Agents. 2010, 36 (1): 28-32. 10.1016/j.ijantimicag.2010.03.016.CrossRefPubMed
10.
go back to reference Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007, 44 (2): 159-177. 10.1086/510393.CrossRefPubMed Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007, 44 (2): 159-177. 10.1086/510393.CrossRefPubMed
11.
go back to reference Goff DA, Bauer KA, Reed EE, Stevenson KB, Taylor JJ, West JE: Is the "low-hanging fruit" worth picking for antimicrobial stewardship programs?. Clin Infect Dis. 2012, 55 (4): 587-592. 10.1093/cid/cis494.CrossRefPubMed Goff DA, Bauer KA, Reed EE, Stevenson KB, Taylor JJ, West JE: Is the "low-hanging fruit" worth picking for antimicrobial stewardship programs?. Clin Infect Dis. 2012, 55 (4): 587-592. 10.1093/cid/cis494.CrossRefPubMed
12.
go back to reference Eckmann C, Lawson W, Nathwani D, Solem CT, Stephens JM, Macahilig C, Simoneau D, Hajek P, Charbonneau C, Chambers R, Li JZ, Haider S: Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: A plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents. 2014, 44 (1): 56-64. 10.1016/j.ijantimicag.2014.04.007.CrossRefPubMed Eckmann C, Lawson W, Nathwani D, Solem CT, Stephens JM, Macahilig C, Simoneau D, Hajek P, Charbonneau C, Chambers R, Li JZ, Haider S: Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: A plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents. 2014, 44 (1): 56-64. 10.1016/j.ijantimicag.2014.04.007.CrossRefPubMed
13.
go back to reference Nathwani D, Eckmann C, Lawson W, Stephens JM, Macahilig C, Solem CT, Simoneau D, Chambers R, Li JZ, Haider S: Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin Microbiol Infect. 2014, doi:10.1111/1469-0691.12632. [Epub ahead of print]. Nathwani D, Eckmann C, Lawson W, Stephens JM, Macahilig C, Solem CT, Simoneau D, Chambers R, Li JZ, Haider S: Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin Microbiol Infect. 2014, doi:10.1111/1469-0691.12632. [Epub ahead of print].
14.
go back to reference Chapman AL, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD: Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother. 2009, 64 (6): 1316-1324. 10.1093/jac/dkp343.CrossRefPubMed Chapman AL, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD: Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother. 2009, 64 (6): 1316-1324. 10.1093/jac/dkp343.CrossRefPubMed
15.
go back to reference Cunha BA: Oral antibiotic therapy of serious systemic infections. Med Clin North Am. 2006, 90 (6): 1197-1222. 10.1016/j.mcna.2006.07.009.CrossRefPubMed Cunha BA: Oral antibiotic therapy of serious systemic infections. Med Clin North Am. 2006, 90 (6): 1197-1222. 10.1016/j.mcna.2006.07.009.CrossRefPubMed
16.
go back to reference Desai M, Franklin BD, Holmes AH, Trust S, Richards M, Jacklin A, Bamford KB: A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay. BMC Infect Dis. 2006, 6: 94-10.1186/1471-2334-6-94.CrossRefPubMedPubMedCentral Desai M, Franklin BD, Holmes AH, Trust S, Richards M, Jacklin A, Bamford KB: A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay. BMC Infect Dis. 2006, 6: 94-10.1186/1471-2334-6-94.CrossRefPubMedPubMedCentral
17.
go back to reference Matthews PC, Conlon CP, Berendt AR, Kayley J, Jefferies L, Atkins BL, Byren I: Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother. 2007, 60 (2): 356-362. 10.1093/jac/dkm210.CrossRefPubMed Matthews PC, Conlon CP, Berendt AR, Kayley J, Jefferies L, Atkins BL, Byren I: Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother. 2007, 60 (2): 356-362. 10.1093/jac/dkm210.CrossRefPubMed
18.
go back to reference Nathwani D, Moitra S, Dunbar J, Crosby G, Peterkin G, Davey P: Skin and soft tissue infections: development of a collaborative management plan between community and hospital care. Int J Clin Pract. 1998, 52 (7): 456-460.PubMed Nathwani D, Moitra S, Dunbar J, Crosby G, Peterkin G, Davey P: Skin and soft tissue infections: development of a collaborative management plan between community and hospital care. Int J Clin Pract. 1998, 52 (7): 456-460.PubMed
19.
go back to reference Parodi S, Rhew DC, Goetz MB: Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections. J Manag Care Pharm. 2003, 9 (4): 317-326.PubMed Parodi S, Rhew DC, Goetz MB: Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections. J Manag Care Pharm. 2003, 9 (4): 317-326.PubMed
20.
go back to reference Seaton RA, Bell E, Gourlay Y, Semple L: Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob Chemother. 2005, 55 (5): 764-767. 10.1093/jac/dki092.CrossRefPubMed Seaton RA, Bell E, Gourlay Y, Semple L: Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob Chemother. 2005, 55 (5): 764-767. 10.1093/jac/dki092.CrossRefPubMed
21.
go back to reference Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, Gainer RB, Kunkel MJ, Yancey RW, Williams DN: Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis. 2004, 38 (12): 1651-1672. 10.1086/420939.CrossRefPubMed Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, Gainer RB, Kunkel MJ, Yancey RW, Williams DN: Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis. 2004, 38 (12): 1651-1672. 10.1086/420939.CrossRefPubMed
22.
go back to reference Dryden M, Saeed K, Townsend R, Winnard C, Bourne S, Parker N, Coia J, Jones B, Lawson W, Wade P, Howard P, Marshall S: Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother. 2012, 67 (9): 2289-2296. 10.1093/jac/dks193.CrossRefPubMed Dryden M, Saeed K, Townsend R, Winnard C, Bourne S, Parker N, Coia J, Jones B, Lawson W, Wade P, Howard P, Marshall S: Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother. 2012, 67 (9): 2289-2296. 10.1093/jac/dks193.CrossRefPubMed
23.
go back to reference Gray A, Dryden M, Charos A: Antibiotic management and early discharge from hospital: an economic analysis. J Antimicrob Chemother. 2012, 67 (9): 2297-2302. 10.1093/jac/dks194.CrossRefPubMed Gray A, Dryden M, Charos A: Antibiotic management and early discharge from hospital: an economic analysis. J Antimicrob Chemother. 2012, 67 (9): 2297-2302. 10.1093/jac/dks194.CrossRefPubMed
24.
go back to reference Lim SC, Doshi V, Castasus B, Lim JKH, Mamun K: Factors causing delay in discharge of elderly patients in an acute care hospital. Ann Acad Med Singapore. 2006, 35: 27-32.PubMed Lim SC, Doshi V, Castasus B, Lim JKH, Mamun K: Factors causing delay in discharge of elderly patients in an acute care hospital. Ann Acad Med Singapore. 2006, 35: 27-32.PubMed
25.
go back to reference Hensher M, Fulop N, Coast J, Jefferys E: The hospital of the future. Better out than in? Alternatives to acute hospital care. BMJ Correct. 1999, 319 (7217): 1127-1130. Hensher M, Fulop N, Coast J, Jefferys E: The hospital of the future. Better out than in? Alternatives to acute hospital care. BMJ Correct. 1999, 319 (7217): 1127-1130.
26.
go back to reference Leekha S, Terrell CL, Edson RS: General principles of antimicrobial therapy. Mayo Clinic Proc Mayo Clinic. 2011, 86 (2): 156-167. 10.4065/mcp.2010.0639.CrossRef Leekha S, Terrell CL, Edson RS: General principles of antimicrobial therapy. Mayo Clinic Proc Mayo Clinic. 2011, 86 (2): 156-167. 10.4065/mcp.2010.0639.CrossRef
27.
go back to reference Eckmann C, Dryden M: Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res. 2010, 15 (12): 554-563.PubMedPubMedCentral Eckmann C, Dryden M: Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res. 2010, 15 (12): 554-563.PubMedPubMedCentral
Metadata
Title
Influence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in Europe
Authors
Dilip Nathwani
Christian Eckmann
Wendy Lawson
Caitlyn T Solem
Shelby Corman
Jennifer M Stephens
Cynthia Macahilig
Damien Simoneau
Richard Chambers
Jim Z Li
Seema Haider
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-14-476

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.